Showing results (961-970 of 1,035) with videos related to

Sort By:
Pageof 104
Psychoneuroendocrinology|June 16, 2010
No association between oxytocin or prolactin gene variants and childhood-onset mood disordersJohn S Strauss, Natalie L Freeman, Sajid A Shaikh, et al.
The Journal of Clinical Endocrinology and Metabolism|June 16, 2012
Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trialDavid W Dempster, Hua Zhou, Robert R Recker, et al.
The Journal of Clinical Endocrinology and Metabolism|March 22, 2013
Abdominal fat is associated with lower bone formation and inferior bone quality in healthy premenopausal women: a transiliac bone biopsy studyAdi Cohen, David W Dempster, Robert R Recker, et al.
The Journal of Clinical Endocrinology and Metabolism|August 12, 2011
Abnormal bone microarchitecture and evidence of osteoblast dysfunction in premenopausal women with idiopathic osteoporosisAdi Cohen, David W Dempster, Robert R Recker, et al.
The Lancet. Diabetes & Endocrinology|May 27, 2017
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extensionHenry G Bone, Rachel B Wagman, Maria L Brandi, et al.
Autophagy|December 9, 2014
Autophagy in osteoblasts is involved in mineralization and bone homeostasisMarie Nollet, Sabine Santucci-Darmanin, Véronique Breuil, et al.
The Journal of Endocrinology|March 23, 2022
AKR1D1 knockout mice develop a sex-dependent metabolic phenotypeLaura L Gathercole, Nikolaos Nikolaou, Shelley E Harris, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 4, 2016
A Longitudinal Study of Skeletal Histomorphometry at 6 and 24 Months Across Four Bone Envelopes in Postmenopausal Women With Osteoporosis Receiving Teriparatide or Zoledronic Acid in the SHOTZ TrialDavid W Dempster, Hua Zhou, Robert R Recker, et al.
Pageof 104